...
首页> 外文期刊>La Presse medicale >Slowing chronic kidney disease progression: hopes and disappointments. Vascular repair of chronic kidney
【24h】

Slowing chronic kidney disease progression: hopes and disappointments. Vascular repair of chronic kidney

机译:慢性肾脏疾病进展缓慢:希望和失望。慢性肾脏的血管修复

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

In chronic kidney disease patients, inexorable renal function decline is reduced by renin-angiotensin system (RAS) blockers. ACE inhibitors and angiotensin receptor blockers decrease blood pressure and proteinuria. Guidelines recommend a reduction of blood pressure to less than 130/80 mmHg and urinary protein excretion below 0.5 g/d. The combined use of a diuretic increases anti-proteinuric effect and blood pressure control of RAS blockers. Drugs as mineralo-corticocoids receptor antagonist and endothelin receptor antagonists reduce further albuminuria in combination with RAS blocker, but side effects need to be precised. Both metabolic acidosis and hyperuricemia represent new therapeutic goals to slow renal function decline in CKD patients. Renal fibrosis treatment and regenerative medicine are stemming and will be important issues for kidney and other organs in the future.
机译:在慢性肾脏疾病患者中,肾素-血管紧张素系统(RAS)阻滞剂可减轻不可阻挡的肾功能下降。 ACE抑制剂和血管紧张素受体阻滞剂可降低血压和蛋白尿。指南建议将血压降低至130/80 mmHg以下,尿蛋白排泄低于0.5 g / d。利尿剂的联合使用可增强RAS阻滞剂的抗蛋白尿作用和血压控制。盐皮质激素受体拮抗剂和内皮素受体拮抗剂等药物与RAS受体阻滞剂联合使用可进一步降低白蛋白尿,但副作用必须精确。代谢性酸中毒和高尿酸血症均代表减慢CKD患者肾功能下降的新治疗目标。肾纤维化的治疗和再生医学正在兴起,并将在未来成为肾脏和其他器官的重要问题。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号